The FDA convenes the first meeting in a decade to consider clawing back approvals from several cancer drugs that have failed to show they extend or improve life. The agency says it has used innovative research shortcuts to speed up the availability of medicines for desperately ill patients. But many researchers say it has failed to crack down on medications that don’t deliver on their early promise, leaving a glut of expensive, unproven cancer drugs on the market.
Read Article: Yahoo News
From the Texas Trial Lawyers Association news release.
